Rating Change
Barclays reiterated its Overweight rating on Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) on August 17, 2026.
reiterateNASDAQ:PHAT
Barclays Reiterates Overweight Rating on Phathom Pharmaceuticals, Inc. (PHAT)
Barclays reiterated its Overweight rating on Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) on August 17, 2026.
At publication ·
What changed
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) · reiterate
- Firm
- Barclays
- Rating
- Overweight to Overweight
- Price at event
- $9.28
- Market capitalization
- $1.0B
At a glance
Key takeaways
- Barclays reiterated an Overweight rating on Phathom Pharmaceuticals (PHAT) on August 17, 2026, with the stock trading at $9.28 and a market capitalization of $1.0 billion.
Market Context
Phathom Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $9.28 with a market capitalization of $1.0B. The stock has declined 11.4% over the past 52 weeks.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Phathom Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Phathom Pharmaceuticals, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 17, 2026 | Barclays | Overweight | N/A |
| Jul 31, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 31, 2026 | Guggenheim | Buy | N/A |
| Jul 30, 2026 | Needham | Buy | N/A |
| Jun 17, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View PHAT Stock Page
Frequently Asked Questions
What does the Overweight rating mean for PHAT?
A rating of Overweight from Barclays reflects the analyst's outlook on Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PHAT forecast page.